Login to Your Account

Earnings Roundup

Regeneron Earnings Driven by Strong Sales of Eylea

By Catherine Shaffer
Staff Writer

Friday, February 15, 2013
Eylea, a newly approved drug for wet age-related macular degeneration, racked up $276 million in sales in 4Q 2012 for Regeneron Pharmaceuticals Inc., and $838 million for the year overall, driving total revenues of $415 million in the 4Q and $1.4 billion for the year.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription